Clinical Trial Details

Overview

Research Study Summary

A double blind placebo controlled study to evaluate the effects of bexagliflozin on hemoglobin A1c in patients with type 2 diabetes and increased risk of cardiovascular adverse events

Purpose

A double blind placebo controlled study to evaluate the effects of bexagliflozin on hemoglobin A1c in patients with type 2 diabetes and increased risk of cardiovascular adverse events

To Learn more

CW ID: 212441
Date Last Changed: January 7, 2016

Clinical Trial Snapshot

Phase
3
Gender
Both Male and Female
Age
40 and up
Overall Status
Recruiting
Lead Sponsor
Theracos Sub, LLC
Duration
2 Years
Facility Type
Out-Patient

Eligibility

Inclusion Criteria

The study population will include:

  • Male or female adult subjects with an age ≥40 years
  • Subjects with a diagnosis of T2DM
  • Subjects with HbA1c values of 7.5 - 11%, inclusive
  • Subjects with fasting plasma glucose (FPG) ≤ 250 mg/dL at screening
  • Subjects who have a regimen for treatment of T2DM that has been stable for the past 3 months. A stable regimen is defined as: no changes in dose or frequency of OHAs or GLP-1 agonists, or < 20% variability in total daily insulin dose
  • Subjects who present with at least one of the following 3 histories:
    • Group 1: A history of atherosclerotic vascular disease as defined by one or more of the following: a) myocardial infarction (MI) or ischemic (non-hemorrhagic) stroke > 3 months but ≤ 5 years prior to screening or b) documented history of coronary, carotid, or peripheral arterial revascularization (coronary artery bypass grafting must have occurred ≥ 5 years prior to screening)
    • Group 2: A history of NYHA class II or class III heart failure (Appendix 4) at the time of screening with a left ventricular ejection fraction (LVEF) ≤ 40% and no subsequent LVEF > 40% documented within 6 months of screening. No more than 200 subjects with class II NYHA heart failure will be randomized in the study
    • Group 3: Age ≥ 55 years with 2 or more of the following:
      • diabetes duration of &gel 10 years
      • uncontrolled hypertension defined as SBP > 140 mmHg despite 3 or more anti-hypertensive medications
      • current smoking
      • urine albumin:creatinine ratio (UACR) > 30 mg/g, e) eGFR of 45 to 60 mL/min/ 1.73 m2, or f) HDL < 1 mmol/L (38 mg/dL)
  • Female subjects of childbearing potential who are willing to use an adequate method of contraception and to not become pregnant for the duration of the study. Adequate contraceptive measures include, but are not limited to, oral contraceptives, intrauterine devices, Depo-Provera, Norplant, hormonal contraceptive implants, bilateral tubal ligation, partner with vasectomy, condom or diaphragm plus contraceptive sponge, foam, or jelly, and abstinence
  • Subjects who are willing and able to return for all clinic visits and to complete all study-required procedures, including self-monitored blood glucose (SMBG) measurement
  • Subjects who receive anti-hypertensive medications at a stable dosage for ≥ 2 weeks prior to randomization
  • Subjects who receive lipid modifying therapy on a stable regimen for 6 weeks prior to randomization
  • Subjects who have SBP < 170 mmHg and DBP < 110 mmHg at screening

Exclusion Criteria

Patients who exhibit any of the following characteristics will be excluded from the study.

  • Diagnosis of type 1 diabetes mellitus or maturity-onset/diabetes of the young (MODY)
  • Hemoglobinopathy that affects HbA1c measurement
  • Frequent symptomatic hypoglycemia (greater than one episode per week on average)
  • Genitourinary tract infection within 6 weeks of screening or history of ≥ 3 genitourinary infections requiring treatment within the last 6 months
  • Cancer, active or in remission for < 3 years (Non-melanoma skin cancer or basal cell carcinoma or carcinoma in situ of the cervix will not be grounds for exclusion)
  • History of alcohol or illicit drug abuse in the past 2 years
  • Evidence of abnormal liver function tests (total bilirubin or alkaline phosphatase > 1.5 x upper limit of normal (ULN) with the exception of isolated Gilbert’s syndrome); or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 x ULN
  • History of MI, stroke or hospitalization for heart failure in the prior 3 months
  • Evidence of NYHA class IV heart failure at screening or randomization
  • Presently scheduled for percutaneous coronary intervention, coronary artery bypass grafting or a surgical procedure
  • Previous treatment with bexagliflozin or EGT0001474
  • Currently or within 3 months of taking any SGLT2 inhibitors (Appendix 3)
  • Any condition, disease, disorder, or clinically relevant laboratory abnormality that, in the opinion of the PI, would jeopardize the subject’s appropriate participation in this study or obscure the effects of treatment
  • Prior renal transplantation or evidence of nephrotic syndrome, defined as a urine albumin: creatinine ratio (UACR) > 2000 mg/g, at screening
  • Implantation of a cardiac resynchronization therapy device within 3 months prior to screening or intent to implant a cardiac resynchronization therapy (CRT) within 6 months following screening
  • Diagnosis of peripartum or chemotherapy-induced cardiomyopathy within 12 months prior to screening
  • Symptomatic bradycardia or second or third degree atrioventricular block without a pacemaker
  • eGFR, as calculated by the modification of diet in renal disease study equation (MDRD), < 45 mL/min/1.73 m2 or requiring dialysis
  • Pregnant or nursing
  • Currently participating in another interventional trial

Contact

Samuel Butman
Verde Valley Medical Center
269 South Candy Lane
Cottonwood, AZ 86326
Phone: (928) 301-7701

View Map

Volunteer for this Trial

If you would like to learn more about participating in this research study, please email the trial contact using the form below. We value your privacy and your information will only be used by the research center to contact you regarding this study.

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.